|
1
|
Cumashi A, Ushakova NA, Preobrazhenskaya
ME, D'Incecco A, Piccoli A, Totani L, Tinari N, Morozevich GE,
Berman AE, Bilan MI, et al: A comparative study of the
anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive
activities of nine different fucoidans from brown seaweeds.
Glycobiology. 17:541–552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li B, Lu F, Wei X and Zhao R: Fucoidan:
Structure and bioactivity. Molecules. 13:1671–1695. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fitton JH, Stringer DN and Karpiniec SS:
Therapies from fucoidan: An update. Mar Drugs. 13:5920–5946. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Senthilkumar K, Manivasagan P, Venkatesan
J and Kim SK: Brown seaweed fucoidan: Biological activity and
apoptosis, growth signaling mechanism in cancer. Int J Biol
Macromol. 60:366–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwak JY: Fucoidan as a marine anticancer
agent in preclinical development. Mar Drugs. 12:851–870. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang P, Liu Z, Liu X, Teng H, Zhang C, Hou
L and Zou X: Anti-metastasis effect of fucoidan from Undaria
pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells. PLoS
One. 9:e1060712014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu L, Sun J, Su X, Yu Q, Yu Q and Zhang P:
A review about the development of fucoidan in antitumor activity:
Progress and challenges. Carbohydr Polym. 154:96–111. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Atashrazm F, Lowenthal RM, Woods GM,
Holloway AF, Karpiniec SS and Dickinson JL: Fucoidan suppresses the
growth of human acute promyelocytic leukemia cells in vitro and in
vivo. J Cell Physiol. 231:688–697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang W, Oda T, Yu Q and Jin JO: Fucoidan
from Macrocystis pyrifera has powerful immune-modulatory effects
compared to three other fucoidans. Mar Drugs. 13:1084–1104. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Centers for Disease Control and Prevention
(CDC), . Cancer survivors-United States, 2007. MMWR Morb Mortal
Wkly Rep. 60:269–272. 2011.PubMed/NCBI
|
|
11
|
Rock CR, Doyle C, Demark-Wahnefried W,
Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK,
Grant B, McCullough M, et al: Nutrition and physical activity
guidelines for cancer survivors. CA Cancer J Clin. 62:243–274.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikeguchi M, Yamamoto M, Arai Y, Maeta Y,
Ashida K, Katano K, Miki Y and Kimura T: Fucoidan reduces the
toxicities of chemotherapy for patients with unresectable advanced
or recurrent colorectal cancer. Oncol Lett. 2:319–322. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi H, Kawaguchi M, Kitamura K,
Narumiya S, Kawamura M, Tengan I, Nishimoto S, Hanamure Y, Majima
Y, Tsubura S, et al: An exploratory study on the anti-inflammatory
effects of fucoidan in relation to quality of life in advanced
cancer patients. Integr Cancer Ther. 17:282–291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whiteside TL and Herberman RB: The role of
natural killer cells in human disease. Clin Immunol Immunopathol.
53:1–23. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imai K, Matsuyama S, Miyake S, Suga K and
Nakachi K: Natural cytotoxic activity of peripheral-blood
lymphocytes and cancer incidence: An 11-year follow-up study of a
general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokita Y, Nakajima K, Mochida H, Iha M and
Nagamine T: Development of a fucoidan-specific antibody and
measurement of fucoidan in serum and urine by sandwich ELISA.
Biosci Biotechnol Biochem. 74:350–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oshimi K, Oshimi Y, Satake M and Mizoguchi
H: Natural killer-mediated lysis of normal and malignant target
cells, and its regulation by monocytes. J Exp Med. 162:472–486.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alkotyfan K, Wiegand S, Müller HH,
Windfuhr JP, Werner JA and Sesterhenn AM: Cyfra 21-1 as a tumor
marker for follow-up of patients with squamous cell carcinoma of
the oropharynx. Anticancer Res. 30:2291–2296. 2010.PubMed/NCBI
|
|
19
|
Aoyagi Y: Carbohydrate-based measurements
on alpha-fetoprotein in the early diagnosis of hepatocellular
carcinoma. Glycoconj J. 12:194–199. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Das V, Kalita J and Pal M: Predictive and
prognostic biomarkers in colorectal cancer: A systematic review of
recent advances and challenges. Biomed Pharmacother. 87:8–19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Triphuridet N, Vidhyarkorn S,
Worakitsitisatorn A, Sricharunrat T, Teerayathanakul N, Auewarakul
C, Chungklay N, Krongthong W, Luengingkasoot S, Sornsamdang G, et
al: Screening values of carcinoembryonic antigen and cytokeratin 19
fragment for lung cancer in combination with low-dose computed
tomography in high-risk populations: Initial and 2-year screening
outcomes. Lung Cancer. 122:243–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Dai D, Chen B, Tang H, Xie X and Wei
W: Clinicopathological and prognostic significance of cancer
antigen 15-3 and carcinoembryonic antigen in breast cancer: A
meta-analysis including 12,993 patients. Dis Markers.
2018:98630922018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laengsri V, Kerdpin U, Plabplueng C,
Treeratanapiboon L and Nuchnoi P: Cervical cancer markers:
Epigenetics and microRNAs. Lab Med. 49:97–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Umekita K, Hashiba Y, Kariya Y, Kubo K,
Miyauchi S, Aizawa A, Umeki K, Nomura H, Kawaguchi T, Matsuda M, et
al: The time-sequential changes of risk factors for adult T-cell
leukemia development in human T-cell leukemia virus-positive
patients with rheumatoid arthritis: A retrospective cohort study.
Mod Rheumatol. 29:795–801. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia J, Song P, Sun Z, Sawakami T, Jia M
and Wang Z: Advances of diagnostic and mechanistic studies of
γ-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov
Ther. 10:181–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Charakorn C, Thadanipon K, Chaijindaratana
S, Rattanasiri S, Numthavaj P and Thakkinstian A: The association
between serum squamous cell carcinoma antigen and recurrence and
survival of patients with cervical squamous cell carcinoma: A
systematic review and meta-analysis. Gynecol Oncol. 150:190–200.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Teishima J, Ohara S, Shinmei S, Inoue S,
Hayashi T, Mochizuki H, Mita K, Shigeta M and Matsubara A:
Normalization of C-reactive protein levels following cytoreductive
nephrectomy in patients with metastatic renal cell carcinoma
treated with tyrosine kinase inhibitors is associated with improved
overall survival. Urol Oncol. 36:339.e9–339.e15. 2018. View Article : Google Scholar
|
|
28
|
Mizuguchi S, Nishiyama N, Iwata T, Nishida
T, Izumi N, Tsukioka T, Inoue K, Uenishi T, Wakasa K and Suehiro S:
Serum sialyl Lewis × and cytokeratin 19 fragment as predictive
factors for recurrence in patients with stage I non-small cell lung
cancer. Lung Cancer. 58:369–375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stephan C, Jung K, Lein M, Sinha P,
Schnorr D and Loening SA: Molecular forms of prostate-specific
antigen and human kallikrein 2 as promising tools for early
diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev.
9:1133–1147. 2000.PubMed/NCBI
|
|
30
|
Ale MT, Maruyama H, Tamauchi H, Mikkelsen
JD and Meyer AS: Fucoidan from Sargassum sp. and fucus vesiculosus
reduces cell viability of lung carcinoma and melanoma cells in
vitro and activates natural killer cells in mice in vivo. Int J
Biol Macromol. 49:331–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Azuma K, Ishihara T, Nakamoto H, Amaha T,
Osaki T, Tsuka T, Imagawa T, Minami S, Takashima O, Ifuku S, et al:
Effects of oral administration of fucoidan extracted from
Cladosiphon okamuranus on tumor growth and survival time in
a tumor-bearing mouse model. Mar Drugs. 10:2337–2348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Negishi H, Mori M, Mori H and Yamori Y:
Supplementation of elderly Japanese men and women with fucoidan
from seaweed increases immune responses to seasonal influenza
vaccination. J Nutr. 143:1794–1798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fehniger TA, Shah MH, Turner MJ, VanDeusen
JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F and
Caligiuri MA: Differential cytokine and chemokine gene expression
by human NK cells following activation with IL-18 or IL-15 in
combination with IL-12: Implications for the innate immune
response. J Immunol. 162:4511–4520. 1999.PubMed/NCBI
|
|
34
|
Liu P, Chen L and Zhang H: Natural killer
cells in liver disease and hepatocellular carcinoma and the NK
cell-based immunotherapy. J Immunol Res. 2018:12067372018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nagamine T, Hayakawa K, Nakazato K and Iha
M: Determination of the active transport of fucoidan derived from
Okinawa Mozuku across the human intestinal Caco-2 cells as assessed
by size-exclusion chromatography. J Chromatogr B Analyt Technol
Biomed Life Sci. 997:187–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Araya N, Takahashi K, Sato T, Nakamura T,
Sawa C, Hasegawa D, Ando H, Aratani S, Yagishita N, Fujii R, et al:
Fucoidan therapy decreases the proviral load in patients with human
T-lymphotropic virus type-1-associated neurological disease.
Antivir Ther. 16:89–98. 2011. View
Article : Google Scholar : PubMed/NCBI
|
